The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women

Gynecological Endocrinology

Volumn 26, Issue 1, 2010, Pages 23-29

  Castelo Branco, Camil ^a   Coloma, Josep Lluis ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adverse effects; Dose finding; Efficacy; Intranasal estradiol; Pharmacokinetics; Safety; Tolerability

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; LIPID;

AREA UNDER THE CURVE; BREAST CANCER; CANCER INVASION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; FEMALE; FRACTURE; GENETIC SCREENING; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MASTALGIA; MENOPAUSE; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; REVIEW; RHINORRHEA; RISK ASSESSMENT; SIDE EFFECT; SKIN IRRITATION; SNEEZING; VASOMOTOR DISORDER;

ADMINISTRATION, INTRANASAL; AUTONOMIC NERVOUS SYSTEM DISEASES; DOSAGE FORMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; NEBULIZERS AND VAPORIZERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASOMOTOR SYSTEM;

EID: 72749107066     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903159698     Document Type: Review

References (25)

1. Castelo-Branco C, Rostro F. Management of menopause. Minerva Ginecol 2006;58:137-152.
2. Castelo-Branco C, Palacios S, Calaf J, Vázquez F, Lanchares JL. Available medical choices for the management of menopause. Maturitas 2005;52(Suppl 1):S61-S70.
3. Krebs EE, Ensrud KE, MacDonals R,Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824-836.
4. Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS. Hormone replacement therapy in menopausal women: past problems and future possibilities. Gynecol Endocrinol 2006; 22:564-577.
5. Musel AL, Warshaw EM. Cutaneous reactions to transdermal therapeutic systems. Dermatitis 2006;17:109-122.
6. Devissaguet J-Ph, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-bestradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24:265-271.
7. Studd J, Pornel B, Marton I, et al. Efficacy and acceptability of intranasal 17 beta-estradiol for menopausal symptoms: randomised dose-response study. Lancet 1999;353:1574-1578.
8. Kuhnz W, Gansau C, Mahler M. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol. Arzneimittelforschung 1993;43:966-973.
9. Pelisser C, et al. Clinical evaluation, dose-finding and acceptability of aerodiol, the pulsed estrogen therapy for treatment of climacteric symptoms. Maturitas 2001;37:181-189.
10. International Menopause Society (2007, May 18). Updated Recommendations On Postmenopausal Hormone Therapy From International Menopause Society. ScienceDaily. Retrieved November 9, 2008, from http://www.sciencedaily.com/ releases/2007/05/070516071742
11. Mattsson LA, et al. Clinical equivalence of intranasal and oral 17 b-estradiol for menopausal symptoms. Am J Obstet Gynecol 2000;182:545-552.
12. Lopes P, et al. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 2000;96:906-912.
13. Buster JE, Koltun WD, Pascual ML, Day WW, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:1343-1351.
14. WHI study Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain 1996-2000.BJOG 2002;109:1319-1330.
15. Blümel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gómez MS, Sarrá S. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 2004;11:57-61.
16. Castelo-Branco C, Ferrer J, Palacios S, Cornago S, Peralta S. Spanish post-menopausal women's viewpoints on hormone therapy. Maturitas 2007;56:420-428.
17. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;(3):CD000402.
18. Gompel A, et al. Endometrial safety and tolerability of Aerodiol1 (intranasal estradiol) for 1 year. Maturitas 2000; 36:209-215.
19. Castelo-Branco C, Palcios S, Vázquez F, Villero J, Ferrer J, Ascaso C, Balasch J. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with fixed dose of 17 b-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. Fertil Steril 2007;88:383-389.
20. Nielsen TF, Ravn P, Bagger YZ, Warming L, Christiansen C. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebocontrolled study. Osteoporos Int 2004;15:168-174.
21. Delmas PD, et al. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route Maturitas 2004;48:85-96.
22. Palacio S. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss. Climacteric 2002;5(Suppl 2):32-39.
23. Chatziavramidis A, Mantsopoulos K, Gennadiou D, Sidiras T. Intranasal complications in women with osteoporosis under treatment with nasal calcitonin spray: case reports and review of the literature. Auris Nasus Larynx 2008;35:417-422.
24. Mun~ oz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol 2004;3:117-132.
25. Studd J, Pornel B, Marton I, Bringer J, Varin C, Tsouderos Y, Christiansen C; Aerodiol Study Group. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Lancet 1999; 353:1574-1578